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Summary
Background COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. 
These complications are likely to have important short-term and long-term consequences for patients, health-care 
utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to 
characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International 
Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK.
Methods We did a prospective, multicentre cohort study in 302 UK health-care facilities. Adult patients aged 19 years 
or older, with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 were included in the study. 
The primary outcome of this study was the incidence of in-hospital complications, defined as organ-specific diagnoses 
occurring alone or in addition to any hallmarks of COVID-19 illness. We used multilevel logistic regression and 
survival models to explore associations between these outcomes and in-hospital complications, age, and pre-existing 
comorbidities.
Findings Between Jan 17 and Aug 4, 2020, 80 388 patients were included in the study. Of the patients admitted to 
hospital for management of COVID-19, 49·7% (36 367 of 73 197) had at least one complication. The mean age of our 
cohort was 71·1 years (SD 18·7), with 56·0% (41 025 of 73 197) being male and 81·0% (59 289 of 73 197) having at least 
one comorbidity. Males and those aged older than 60 years were most likely to have a complication (aged ≥60 years: 
54·5% [16 579 of 30 416] in males and 48·2% [11 707 of 24 288] in females; aged <60 years: 48·8% [5179 of 10 609] in 
males and 36·6% [2814 of 7689] in females). Renal (24·3%, 17 752 of 73 197), complex respiratory (18·4%, 13 486 of 
73 197), and systemic (16·3%, 11 895 of 73 197) complications were the most frequent. Cardiovascular (12·3%, 8973 of 
73 197), neurological (4·3%, 3115 of 73 197), and gastrointestinal or liver (0·8%, 7901 of 73 197) complications were 
also reported.
Interpretation Complications and worse functional outcomes in patients admitted to hospital with COVID-19 are 
high, even in young, previously healthy individuals. Acute complications are associated with reduced ability to self-
care at discharge, with neurological complications being associated with the worst functional outcomes. COVID-19 
complications are likely to cause a substantial strain on health and social care in the coming years. These data will 
help in the design and provision of services aimed at the post-hospitalisation care of patients with COVID-19.
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Introduction
Many people across the world have been hospitalised 
with COVID-19 following SARS-CoV-2 infection. Evi-
dence has established that these patients have high 
mortality rates (26%), and up to 17% of patients admitted 
to hospital will require ventilatory support and critical 
care.1 Several case reports, cross-sectional studies, and 
case-control studies have described the presence of 
non-respiratory complications in those with COVID-19 
and suggest that these are likely to be associated with 
poor outcomes.2–4
Understanding the possible complications of COVID-19 
is important for patient management and provision in 
health-care systems. For patients, information around in-
hospital complication rates are important for decision 
making about treatment, long-term planning, possible 
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resumption of normal activity and, more recently, 
vaccination. For health-care systems, these data are vital 
to inform immediate preparedness measures (ie, alloca-
tion of resources, equipment, and staffing) and also for 
long-term planning of health-care delivery to a population 
that might have incurred additional morbidity due to 
COVID-19.
A substantial proportion of patients with COVID-19 go 
on to develop critical illness and require organ support. It 
is widely recognised that survival following critical illness 
is accompanied by a substantial burden of additional 
physical and mental health morbidity that cannot be 
measured by mortality outcomes.5,6 Mortality has been 
widely used as an outcome in epidemiological studies 
and randomised controlled trials for patients with 
COVID-19 but fails to capture the immediate short-term 
health issues faced by survivors, including in-hospital 
complications and functional outcomes. In patients 
with COVID-19 undergoing surgery, high rates of post-
procedural mortality and complications have been noted, 
but systematic characterisation of hospitalised patients 
with COVID-19 is lacking.7 In other non-SARS-CoV-2 
viral illnesses, for example influenza, short-term 
complications such as myocardial infarction, acute 
kidney injury, and stroke are common and can cause 
greater morbidity than the initial infection itself.6,8–11 
Understanding which patients develop short-term 
complications might also allow clinicians and researchers 
to develop care pathways and interventions to mitigate 
the impact of complications. As many patients with 
COVID-19 are critically unwell, identifying the burden 
of short-term morbidity could be useful to understand 
the long-term burden on health-care systems and society 
for those who survive COVID-19.
We have previously characterised the clinical features 
of patients admitted to hospital with COVID-19 using the 
International Severe Acute Respiratory and Emerging 
Infections Consortium (ISARIC) WHO Clinical Char-
acterisation Protocol UK (CCP-UK) for severe emerging 
infections.1 The aim of this study was to describe the 
short-term complications, beyond those associated with 
the presenting features of COVID-19 and severe acute 
respiratory infection.
Methods
Study design and participants
The ISARIC WHO CCP-UK protocol was developed by 
an international consensus in 2012–14 and reactivated in 
response to the COVID-19 pandemic on Jan 17, 2020.12 
Our study is an actively recruiting prospective cohort 
study across 302 health-care facilities in the UK. Adult 
patients aged 19 years and older, who were admitted to 
hospital between Jan 17 and Aug 4, 2020, with confirmed 
or highly suspected SARS-CoV-2 infection leading to 
COVID-19 were included in this analysis; overall study 
recruitment is ongoing. We used this WHO age cutoff13 
as children exhibit other patterns of complica-
tions including multisystem inflammatory syndrome. 
Confirmation of SARS-CoV-2 was done using RT-PCR. 
Highly suspected cases were eligible for inclusion, given 
Research in context
Evidence before this study
We did a systematic search of the MEDLINE and PubMed 
databases on Dec 5, 2020, using the search terms 
(“in-hospital” OR “hospital”) AND (“SARS-CoV-2” OR 
“COVID” OR “COVID-19”) AND “complications”. We limited 
dates of searches from Jan 1, 2020, to the date the search was 
conducted. No language restrictions applied. Data from 
other areas of health care, such as surgery, suggest that 
patients with COVID-19 are at greater risk of subsequent 
complications, but systematic characterisation of 
complications in these patients has not yet been undertaken 
in large multicentre studies of patients admitted to hospital. 
Most COVID-19 studies have focused on mortality and 
respiratory support outcomes. Characterising the burden of 
complications is important for health-care system 
preparedness for further waves of infection, determining 
future population morbidity, understanding the full 
repercussions of COVID-19 for society, and for informing 
future research and clinical guidelines. The current literature 
is comprised of several small cohort or case-control studies 
that focus on specific organ systems or conditions. There are 
few prospective systematically collected data describing the 
in-hospital complications of COVID-19.
Added value of this study
Hospitalised adult patients aged 19 and over with COVID-19 
frequently had complications, even in younger age groups and in 
those with few pre-existing comorbidities. Occurrence of 
complications was associated with a significantly reduced ability 
to self-care at discharge, which was seen in all age and 
comorbidity groups. Although patients aged younger than 
50 years are at low risk of dying from COVID-19, we found high 
rates of complications across all age groups.
Implications of all the available evidence
In patients admitted to hospital with COVID-19, there is a burden 
of immediate complications affecting all age groups. Many of the 
complications identified are likely to have important long-term 
effects. Health-care systems and policy makers should prepare for 
increases in population morbidity arising from COVID-19 and its 
subsequent complications. As complications following COVID-19 
are common across all age groups and comorbidities, public 
health messaging around the risk COVID-19 poses to younger 
otherwise healthy people should be considered alongside vaccine 
prioritisation. Further studies are required to understand the 
medium-term to long-term effects of COVID-19 and how 
immediate complications may lead to lasting morbidity.
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that SARS-CoV-2 was an emergent pathogen at the time 
of protocol activation and laboratory confirmation was 
dependent on local availability of testing.
Study materials including protocol, revision history, 
case report forms, study information, and consent forms 
are available online.14 All patients who provided biological 
samples were required to provide informed, written 
consent. If patients only provided routinely collected 
clinical data, written consent was not required. Ethical 
approval was given by the South Central–Oxford C 
Research Ethics Committee in England (reference 
13/SC/0149) and the Scotland A Research Ethics 
Committee (reference 20/SS/0028). The study is reported 
in line with the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines.15
Procedures
Data collected by research nurses and volunteer medical 
students were entered into a standardised electronic 
case report form within a secure research electronic 
data capture database.16 Multiple timepoints were 
captured, including admission, hospital stay at days 1, 3, 
and 9, and discharge or status at 28 days if not 
discharged. Data were collected according to a detailed 
protocol, which was updated to reflect developments 
over the course of the pandemic. Participant char-
acteristics including age, sex at birth, physiological 
parameters at presentation, and comorbidities were also 
recorded. Comorbidities included asthma, chronic 
cardiac disease, chronic haematological disease, chronic 
kidney disease, chronic neurological disease, chronic 
pulmonary disease, HIV/AIDS, history of malignancy, 
liver disease, clinician-defined obesity, rheumatological 
disorders, and smoking. Deprivation was calculated by 
mapping individual postcodes to their corresponding 
Index of Multiple Deprivation (IMD) using the Office 
for National Statistics postcode data. Using national 
data, we calculated deprivation quintiles, with the first 
quintile being the least deprived and the fifth quintile 
the most deprived. For patients where postcodes were 
missing, the average IMD rank, weighted by population 
in each lower super output area for a given hospital 
catchment area, was used.
Outcomes
The primary outcome of this study was the incidence 
of in-hospital complications, defined as organ-specific 
diagnoses occurring alone or in addition to any 
hallmarks of COVID-19 illness (appendix p 1–2). All 
complications were recorded so that total morbidity 
could be described, not just those directly attributable 
to COVID-19. Although COVID-19 is a multisystem 
disease, severe respiratory infection was considered 
characteristic of COVID-19 and was not regarded as a 
complication. Data were collected on organ-specific 
complications including complex respiratory (bacterial 
pneumonia, acute respiratory distress syndrome 
[ARDS], empyema, pneumothorax, and pleural effusion), 
neurological (meningitis, encephalitis, seizure, and 
stroke), cardio vascular (thromboembolism, heart failure, 
myocarditis, endocarditis, arrhythmia, cardiomyopathy, 
myocardial ischaemia, and cardiac arrest), acute kidney 
injury, gastrointestinal (acute liver injury, pancreatitis, 
and gastrointestinal haemorrhage), and other systemic 
complications (coagulopathy, disseminated intravascular 
coagulation, anaemia, and bloodstream infection). The 
occurrence of complications was determined from 
routine clinical records by local investigators with 
the exceptions of bloodstream infection and micro-
biologically confirmed bacterial pneumonia. These were 
defined based on recorded results from sputum, deep 
respiratory, or blood cultures and restricted to instances 
where clinically signifi cant organisms were detected 
in the sample. Blood stream infection was defined 
as growth of clinically significant bacteria (excluding 
coagulase-negative Staphylococci) or fungus recorded 
from blood culture or PCR of the blood. Results 
considered to represent contamination or colonisation 
were excluded. Owing to the difficulties of obtaining 
lower respiratory tract samples to confirm bacterial 
pneumonia and the low positivity rates, we present both 
highly likely and suspected bacterial pneumonia in the 
appendix (pp 1–2).
The existence of likely ARDS was described clinically or 
defined as one of the following combinations: receiving 
extracorporeal membrane oxygenation; being nursed in 
a prone position and receiving invasive mechanical 
ventilation; or receiving mechanical ventilation with a 
ratio of partial pressure of arterial oxygen to fraction of 
inspired air of 300 mm Hg or less. For acute kidney injury 
and acute liver injury, we used laboratory measurements 
with internationally recognised grading systems to detect 
complications that could have been missed. Acute kidney 
injury was defined as a creatinine rise which corresponded 
to the Kidney Disease Improving Global Outcomes 
stage 1 or above definition17 (creatinine rise ≥1·5 × baseline 
value or by ≥26·5 µmol/L). We did not incorporate urine 
output into this definition as this parameter is not 
universally recorded for all patients, particularly outwith 
critical care. Acute liver injury was defined as one of the 
following: an international normalised ratio rise of 
2·5 times or greater than the lowest entered value; an 
international normalised ratio of more than 4·5 (in the 
absence of warfarin therapy); an alanine amino transferase 
rise of more than 10 times the lowest value; an alanine 
aminotransferase of more than 150 IU/L; a bilirubin 
rise of more than 15 µmol/L; or a bilirubin greater 
than 55 µmol/L (in the absence of any pre-existing liver 
disease). In those who survived, we also captured 
information on whether self-care ability was the same or 
worse than before hospital admission at time of discharge, 
defined clinically as the change in support required 
before and after hospital admission. For this outcome, if 
patients required ongoing hospital care, we defined this 
See Online for appendix
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outcome as worse than before onset of COVID-19 illness 
due to these ongoing care requirements.
Statistical analysis
Continuous data are presented as a mean with SD where 
data are normally distributed and as a median with 
the 25th and 75th centiles for non-parametric data. 
Categorical data are summarised as frequencies and 
percentages. Differences between groups for continuous 
normally distributed data were tested using Welch’s 
t test for two groups or ANOVA when there were more 
than two groups. Non-parametric continuous data were 
tested using a Mann-Whitney U test for two groups or 
Kruskall-Wallis test for three or more groups. Differences 
across categorical data were tested using the χ² test or 
Fisher’s exact test when expected cell counts were less 
than five. Analysis of complication co-occurrence was 
done using the Jaccard similarity index and represented 
visually as heatmaps with dendrograms constructed 
from complete hierarchical clustering results. We only 
included patients who had completed outcomes, with at 
least 2 months of follow-up. There were low rates of 
missing data and therefore multiple imputation was not 
used.
To explore if the number of complications and which 
specific complications were associated with mortality 
(dependent variable), complication variables were entered 
independently into Cox proportional hazards models and 
adjusted for other potentially confounding factors. These 
data were described using Kaplan-Meier plots and 
modelled using Cox proportional hazards regression. 
Reported date of symptom onset was taken as day 0. 
Discharge from hospital was considered an absorbing 
state (once discharged, patients were considered no 
longer at risk of death); thus discharge did not compete 
with death. The proportional hazards assumption was 
checked.
To observe whether complications were associated with 
increased severity of initial disease, we used the ISARIC 4C 
Mortality Score, quick sequential organ failure assessment 
(qSOFA), and National Early Warning Score 2 (NEWS2) 
on admission or time of symptom start to examine the 
relationship between severity and presence of any in-
hospital complications.18 These scores are commonly used 
in clinical practice to identify patients with deteriorating 
or critical illness and risk of subsequent death in general 
adult hospital popula tions (NEWS2 and qSOFA) or in 
COVID-19 patients (4C Mortality Score). We calculated the 
score for each adult patient in the dataset and plotted each 
score against the observed incidence of complications in 
each score group.
Multilevel logistic regression models were constructed 
to identify associations between patient characteristics 
(potential confounders, including patient demographics 
and existing comorbidities) and the development of 
specific complications, worse self-care ability on dis-
charge, and the requirement for ongoing hospital care. 
For all models, variable selection was done based on 
clinical plausibility, and final models were selected 
based on clinical relevance guided by minimisation of 
the Akaike information criterion. Centre-level variation 
was accounted for using mixed-effects models that 
included hospital as a random effect and patient-level 
variables as fixed effects. We did stratified analyses to 
focus on survivors and on those admitted to critical 
care.
To identify which patient groups are at the highest risk of 
complications and mortality, we used generalised additive 
models and generated risk estimates by age, sex, and 
comorbidity status. Generalised additive models accom-
modated potential non-linear relationships between 
variables with the inclusion of penalised thin-plate 
regression splines on continuous variables. We did this 
for each organ-specific complication outcome, as well as 
testing the associations between organ-specific complica-
tions and death. Models were adjusted for age, sex, 
comorbidity status and deprivation (IMD quintile). First 
and second order interactions were explored and included 
where they significantly contributed to model fitting. We 
ran 100 bootstrap replicates for each model to provide a 
visual representation of the distribution.
All statistical analyses were done with R (version 3.6.3) 
using the tidyverse, finalfit, mcgv, survival, stringdist, 
janitor, and Hmisc packages.
Role of the funding source
The funders of the study had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report.
Results
Between Jan 17 and Aug 4, 2020, 80 388 patients were 
included in the CCP-UK study (figure 1). Of these, 
75 276 were adults aged 19 years or older, of which 97·2% 
(73 197 of 75 276) had any com plication outcome available 
for analysis. The overall mortality rate was 31·5% 
(23 092 of 73 197), and the overall complication rate was 
49·7% (36 367 of 73 197 had at least one complication). In 
surviving patients, 43·5% (21 784 of 50 105) had at least 
one complication. Proportions of patients having at least 
one complication were highest in age groups of over 
60 years (table 1). Missing data for each variable were 
under 10% for nearly all patient characteristics included 
in the study (appendix pp 3–4). Of all patients included, 
85·9% (62 894 of 73 197) had a positive SARS-CoV-2 
RT-PCR test. Patients who did not have a positive swab 
had the same or slightly lower rates of complications 
overall and organ-specific complications (appendix p 3).
The mean age of patients included in our study was 
71·1 years old (SD 18·7), with the majority of those included 
being male (table 1). One or more comorbidities were 
present in 81·0% (59 289 of 73 197) of the cohort. Chronic 
cardiac disease was the most common comorbidity, 
followed by chronic pulmonary disease and chronic kidney 
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disease. Most of the study cohort consisted of White 
people.
In adult patients with COVID-19, renal, complex 
respiratory, car dio vascular, neurological, gastrointestinal, 
and systemic complications were reported (table 1). 
Specific complications within each organ system were 
also reported, with acute kidney injury, probable ARDS, 
liver injury, anaemia, and cardiac arrhythmia being the 
most common (appendix pp 4–5). The incidence of acute 
kidney injury increased with age and was most common 
in patients aged between 60 and 90 years, with males at 
greater risk. Patients with chronic kidney disease were at 
the highest risk of acute kidney injury, with 39·8% 
(4785 of 12 182) developing acute kidney injury versus 
21·6% (11 962 of 55 458) in patients without chronic 
kidney disease. Cardiac complications were more 
frequently observed with increasing age and in patients 
with existing cardiac disease. In those with existing 
cardiac disease, 19·9% (4496 of 22 563) developed a 
cardiac complication compared with 8·9% (4077 of 45 563) 
in those without previous cardiac disease. In contrast, 
liver injury was most frequently seen in younger age 
groups (aged <60 years), with the highest rates occurring 
in males. Liver injury was more common in patients 
with pre-existing moderate or severe liver disease 
(300 [22·4%] of 1340) compared with those without liver 
injury (4097 [6·2%] of 65 646). Complication rates were 
com parable across White, South Asian, and East Asian 
ethnic and racial groups, but were highest in Black 
people (57·8% [1433 of 2480] in Black patients vs 
49·1% [26 431 of 53 780] in White patients; table 1). Rates 
of acute kidney injury were highest in Black patients 
(822 [33·1%] of 2480) compared with White patients 
(12 896 [24·0%] of 53 780). Patients with obesity were 
1·6 times more likely to have respiratory complications 
(2059 [28·1%] of 7329) compared with those who did not 
have obesity (9498 [17·8%] of 53 415; table 1). Patients who 
had obesity were also 1·3 times more likely to have renal 
complications (2208 [30·1%] of 7329) compared with 
those who did not have obesity (12 656 [23·7%] of 53 415; 
table 1).
Suspected bacterial pneumonia was the most common 
respiratory complication (appendix pp 6–7), but when the 
definition incorporated positive microbiological testing 
(highly likely bacterial pneumonia), the incidence of 
highly likely bacterial pneumonia was lower. Acute 
kidney injury (Jaccard index 0·23), likely ARDS (Jaccard 
index 0·17), anaemia (Jaccard index 0·13), and liver 
injury (Jaccard index 0·10) were most likely to co-occur 
with death (appendix p 35).
Having at least one complication was common across 
all demographic groups, with the lowest rates in patients 
aged 19–29 years with no comorbidity (178 [21·2%] of 839) 
and the highest rates in patients aged 60–69 years who 
had two or more comorbidities (3340 [57·9%] of 5767; 
appendix pp 8–11). The incidence of com plications rose 
with increasing age occurring in 38·9% (3596 of 9249) in 
those aged 19–49 years and 51·3% (32 771 of 63 948) in 
those aged 50 years and older (figure 2A). The number of 
complications increased with the number of pre-existing 
comorbidities, particularly in individuals aged 40 years 
and older (figure 2A and appendix pp 8–11). Complications 
were higher in males compared with females, and males 
were more likely to have complications than females, 
with males aged older than 60 years the most likely group 
to have at least one complication (aged <60 years: 36·6% 
[2814 of 7689] in females and 48·8% [5179 of 10 609] in 
males; aged ≥60 years: 48·2% [11 707 of 24 288] in females 
and 54·5% [16 579 of 30 416] in males; figure 2A and 
appendix pp 4–5). Young males (aged 19–29 years) without 
comorbidities were significantly more likely to have 
complications than young females (aged 19–29 years) 
without comorbidities (28·4% [94 of 331] in males and 
16·6% [84 of 505] in females; figure 2A). When we 
stratified by mortality, complications occurred more 
frequently in patients who died (14 583 [63·2%] of 23 092), 
but were still common in survivors (21 784 [43·5%] 
of 50 105; appendix pp 12–13) and there were direct 
Figure 1: Study profile
80 388 patients included using the WHO Clinical 
Characterisation Protocol UK
76 744 patients confirmed or highly suspected 
with SARS-CoV-2  
3644 patients excluded
 2915 duplicated patient records 
 729 found to be ineligible or withdrew 
consent 
75 276 patients aged ≥19 included in the analysis






7901 gastrointestinal and liver
11 895 systemic
1468 patients excluded as they were aged 
<19 years
2079 had no outcome data available
73 197 patients had any complication outcome 
available for analysis 
36 830 patients had no in-hospital 
complication
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Patients having complications Organ-specific complications
Total number of 
patients
Any complication Systemic Renal Gastrointestinal 
(including liver)
Cardiovascular Neurological Respiratory*
Total number of 
patients
73 197 36 367 (49·7%) 11 895 (16·3%) 17 752 (24·3%) 7901 (10·8%) 8973 (12·3%) 3115 (4·3%) 13 486 (18·4%)
Age on admission, years
19–29 1500 (2·0%) 411 (1·1%) 147 (1·2%) 126 (0·7%) 139 (1·8%) 47 (0·5%) 38 (1·2%) 145 (1·1%)
30–39 2753 (3·8%) 1015 (2·8%) 376 (3·2%) 353 (2·0%) 365 (4·6%) 134 (1·5%) 91 (2·9%) 457 (3·4%)
40–49 4996 (6·8%) 2170 (6·0%) 731 (6·1%) 874 (4·9%) 740 (9·4%) 370 (4·1%) 162 (5·2%) 1169 (8·7%)
50–59 9101 (12·4%) 4418 (12·1%) 1504 (12·6%) 2078 (11·7%) 1468 (18·6%) 847 (9·4%) 352 (11·3%) 2263 (16·8%)
60–69 11 139 (15·2%) 5954 (16·4%) 2008 (16·9%) 3055 (17·2%) 1578 (20·0%) 1389 (15·5%) 500 (16·1%) 2767 (20·5%)
70–79 16 563 (22·6%) 8549 (23·5%) 2727 (22·9%) 4318 (24·3%) 1644 (20·8%) 2220 (24·7%) 725 (23·3%) 2978 (22·1%)
80–89 19 900 (27·2%) 10 207 (28·1%) 3241 (27·2%) 5161 (29·1%) 1478 (18·7%) 2888 (32·2%) 941 (30·2%) 2761 (20·5%)
≥90 7245 (9·9%) 3643 (10·0%) 1161 (9·8%) 1787 (10·1%) 489 (6·2%) 1078 (12·0%) 306 (9·8%) 946 (7·0%)
Sex at birth
Female 31 977 (43·7%) 14 521 (39·9%) 4872 (41·0%) 6612 (37·2%) 2690 (34·0%) 3539 (39·4%) 1289 (41·4%) 4951 (36·7%)
Male 41 025 (56·0%) 21 758 (59·8%) 7001 (58·9%) 11 097 (62·5%) 5199 (65·8%) 5415 (60·3%) 1822 (58·5%) 8504 (63·1%)
Data missing 195 (0·3%) 88 (0·2%) 22 (0·2%) 43 (0·2%) 12 (0·2%) 19 (0·2%) 4 (0·1%) 31 (0·2%)
Deprivation, IMD quintile†
1 10 408 (14·2%) 5201 (14·3%) 1773 (14·9%) 2437 (13·7%) 1152 (14·6%) 1384 (15·4%) 466 (15·0%) 1885 (14·0%)
2 12 853 (17·6%) 6439 (17·7%) 2147 (18·0%) 2996 (16·9%) 1431 (18·1%) 1634 (18·2%) 552 (17·7%) 2305 (17·1%)
3 15 822 (21·6%) 7855 (21·6%) 2595 (21·8%) 3793 (21·4%) 1631 (20·6%) 1986 (22·1%) 633 (20·3%) 3035 (22·5%)
4 16 104 (22·0%) 8069 (22·2%) 2621 (22·0%) 4101 (23·1%) 1748 (22·1%) 2012 (22·4%) 718 (23·0%) 3083 (22·9%)
5 17 997 (24·6%) 8801 (24·2%) 2759 (23·2%) 4424 (24·9%) 1939 (24·5%) 1956 (21·8%) 745 (23·9%) 3177 (23·6%)
Data missing 13 (<0·1%) 2 (<0·1%) 0 1 (<0·1%) 0 1 (<0·1%) 1 (<0·1%) 1 (<0·1%)
Race or ethnicity
White 53 780 (73·5%) 26 431 (72·7%) 8678 (73·0%) 12 896 (72·6%) 5438 (68·8%) 6624 (73·8%) 2282 (73·3%) 9173 (68·0%)
South Asian 3318 (4·5%) 1630 (4·5%) 593 (5·0%) 799 (4·5%) 441 (5·6%) 369 (4·1%) 102 (3·3%) 777 (5·8%)
East Asian 484 (0·7%) 249 (0·7%) 96 (0·8%) 113 (0·6%) 82 (1·0%) 55 (0·6%) 15 (0·5%) 142 (1·1%)
Black 2480 (3·4%) 1433 (3·9%) 508 (4·3%) 822 (4·6%) 346 (4·4%) 306 (3·4%) 114 (3·7%) 627 (4·6%)
Other ethnic 
minority‡
4646 (6·3%) 2435 (6·7%) 751 (6·3%) 1145 (6·4%) 641 (8·1%) 491 (5·5%) 203 (6·5%) 1171 (8·7%)
Data missing 8489 (11·6%) 4189 (11·5%) 1269 (10·7%) 1977 (11·1%) 953 (12·1%) 1128 (12·6%) 399 (12·8%) 1596 (11·8%)
Diabetes
No 49 765 (75·8%) 24 481 (73·6%) 7878 (71·9%) 11 265 (69·7%) 5694 (77·9%) 5948 (72·4%) 2173 (77·7%) 9194 (74·3%)
Yes 15 855 (24·2%) 8792 (26·4%) 3081 (28·1%) 4891 (30·3%) 1615 (22·1%) 2266 (27·6%) 625 (22·3%) 3173 (25·7%)
Obesity
No 53 415 (73·0%) 26 397 (72·6%) 8476 (71·3%) 12 656 (71·3%) 5784 (73·2%) 6331 (70·6%) 2304 (74·0%) 9498 (70·4%)
Yes 7329 (10·0%) 4230 (11·6%) 1583 (13·3%) 2208 (12·4%) 985 (12·5%) 1226 (13·7%) 296 (9·5%) 2059 (15·3%)
Data missing 12 453 (17·0%) 5740 (15·8%) 1836 (15·4%) 2888 (16·3%) 1132 (14·3%) 1416 (15·8%) 515 (16·5%) 1929 (14·3%)
Chronic cardiac disease
No 45 563 (62·2%) 21 808 (60·0%) 7117 (59·8%) 10 400 (58·6%) 5332 (67·5%) 4077 (45·4%) 1923 (61·7%) 8787 (65·2%)
Yes 22 563 (30·8%) 12 758 (35·1%) 4235 (35·6%) 6436 (36·3%) 2201 (27·9%) 4496 (50·1%) 995 (31·9%) 4025 (29·8%)
Data missing 5071 (6·9%) 1801 (5·0%) 543 (4·6%) 916 (5·2%) 368 (4·7%) 400 (4·5%) 197 (6·3%) 674 (5·0%)
Chronic pulmonary disease
No 55 604 (76·0%) 27 916 (76·8%) 9261 (77·9%) 13 619 (76·7%) 6404 (81·1%) 6665 (74·3%) 2461 (79·0%) 10 468 (77·6%)
Yes 12 235 (16·7%) 6472 (17·8%) 2002 (16·8%) 3143 (17·7%) 1100 (13·9%) 1791 (20·0%) 444 (14·3%) 2289 (17·0%)
Data missing 5358 (7·3%) 1979 (5·4%) 632 (5·3%) 990 (5·6%) 397 (5·0%) 517 (5·8%) 210 (6·7%) 729 (5·4%)
Asthma
No 58 352 (79·7%) 29 806 (82·0%) 9782 (82·2%) 14 657 (82·6%) 6525 (82·6%) 7286 (81·2%) 2572 (82·6%) 10 852 (80·5%)
Yes 9298 (12·7%) 4447 (12·2%) 1482 (12·5%) 2039 (11·5%) 977 (12·4%) 1141 (12·7%) 320 (10·3%) 1849 (13·7%)
Data missing 5547 (7·6%) 2114 (5·8%) 631 (5·3%) 1056 (5·9%) 399 (5·0%) 546 (6·1%) 223 (7·2%) 785 (5·8%)
(Table 1 continues on next page)
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relationships between worse survival and increasing 
numbers of complications (figure 2B).
After adjusting for age, sex, deprivation, comorbidities, 
and study centre, increasing age and male sex were 
significant independent predictors for developing any 
complication and for all organ-specific complications 
except for gastrointestinal and liver complications, 
which younger patients were more likely to experience 
(figure 3A and appendix pp 36–44). Those with pre-
existing comorbidities that affected a specific organ 
Patients having complications Organ-specific complications
Total number of 
patients
Any complication Systemic Renal Gastrointestinal 
(including liver)
Cardiovascular Neurological Respiratory*
(Continued from previous page)
Chronic kidney disease
No 55 458 (75·8%) 26 793 (73·7%) 8582 (72·1%) 11 962 (67·4%) 6284 (79·5%) 6434 (71·7%) 2368 (76·0%) 10 654 (79·0%)
Yes 12 182 (16·6%) 7503 (20·6%) 2661 (22·4%) 4785 (27·0%) 1166 (14·8%) 2008 (22·4%) 525 (16·9%) 2070 (15·3%)
Data missing 5557 (7·6%) 2071 (5·7%) 652 (5·5%) 1005 (5·7%) 451 (5·7%) 531 (5·9%) 222 (7·1%) 762 (5·7%)
Moderate or severe liver disease
No 65 646 (89·7%) 33 005 (90·8%) 10 769 (90·5%) 16 111 (90·8%) 6879 (87·1%) 8162 (91·0%) 2764 (88·7%) 12 314 (91·3%)
Yes 1340 (1·8%) 916 (2·5%) 358 (3·0%) 413 (2·3%) 528 (6·7%) 179 (2·0%) 96 (3·1%) 281 (2·1%)
Data missing 6211 (8·5%) 2446 (6·7%) 768 (6·5%) 1228 (6·9%) 494 (6·3%) 632 (7·0%) 255 (8·2%) 891 (6·6%)
Mild liver disease
No 65 784 (89·9%) 33 164 (91·2%) 10 837 (91·1%) 16 169 (91·1%) 7096 (89·8%) 8178 (91·1%) 2792 (89·6%) 12 338 (91·5%)
Yes 1035 (1·4%) 635 (1·7%) 240 (2·0%) 294 (1·7%) 269 (3·4%) 132 (1·5%) 60 (1·9%) 222 (1·6%)
Data missing 6378 (8·7%) 2568 (7·1%) 818 (6·9%) 1289 (7·3%) 536 (6·8%) 663 (7·4%) 263 (8·4%) 926 (6·9%)
Chronic neurological disorder
No 58 511 (79·9%) 29 546 (81·2%) 9725 (81·8%) 14 440 (81·3%) 6700 (84·8%) 7357 (82·0%) 2048 (65·7%) 11 352 (84·2%)
Yes 8802 (12·0%) 4559 (12·5%) 1467 (12·3%) 2167 (12·2%) 729 (9·2%) 1024 (11·4%) 845 (27·1%) 1309 (9·7%)
Data missing 5884 (8·0%) 2262 (6·2%) 703 (5·9%) 1145 (6·4%) 472 (6·0%) 592 (6·6%) 222 (7·1%) 825 (6·1%)
Malignant neoplasm
No 60 050 (82·0%) 29 952 (82·4%) 9485 (79·7%) 14 643 (82·5%) 6620 (83·8%) 7378 (82·2%) 2564 (82·3%) 11 283 (83·7%)
Yes 7072 (9·7%) 4075 (11·2%) 1675 (14·1%) 1932 (10·9%) 819 (10·4%) 994 (11·1%) 307 (9·9%) 1341 (9·9%)
Data missing 6075 (8·3%) 2340 (6·4%) 735 (6·2%) 1177 (6·6%) 462 (5·8%) 601 (6·7%) 244 (7·8%) 862 (6·4%)
Chronic haematological disease
No 64 082 (87·5%) 32 079 (88·2%) 10 150 (85·3%) 15 622 (88·0%) 6958 (88·1%) 7906 (88·1%) 2737 (87·9%) 12 003 (89·0%)
Yes 2982 (4·1%) 1907 (5·2%) 1017 (8·5%) 942 (5·3%) 447 (5·7%) 461 (5·15) 122 (3·9%) 600 (4·4%)
Data missing 6133 (8·4%) 2381 (6·5%) 728 (6·1%) 1188 (6·7%) 496 (6·3%) 606 (6·8%) 256 (8·2%) 883 (6·5%)
HIV/AIDs
No 65 920 (90·1%) 33 268 (91·5%) 10 828 (91·0%) 16 190 (91·2%) 7256 (91·8%) 8195 (91·3%) 2809 (90·2%) 12 360 (91·7%)
Yes 256 (0·3%) 149 (0·4%) 57 (0·5%) 82 (0·5%) 42 (0·5%) 28 (0·3%) 13 (0·4%) 57 (0·4%)
Data missing 7021 (9·6%) 2950 (8·1%) 1010 (8·5%) 1480 (8·3%) 603 (7·6%) 750 (8·4%) 293 (9·4%) 1069 (7·9%)
Rheumatological disorder
No 59 168 (80·8%) 29 823 (82·0%) 9663 (81·2%) 14 540 (81·9%) 6708 (84·9%) 7294 (81·3%) 2512 (80·6%) 11 245 (83·4%)
Yes 7724 (10·6%) 4075 (11·2%) 1462 (12·3%) 1961 (11·0%) 701 (8·9%) 1061 (11·8%) 353 (11·3%) 1358 (10·1%)
Data missing 6305 (8·6%) 2469 (6·8%) 770 (6·5%) 1251 (7·0%) 492 (6·2%) 618 (6·9%) 250 (8·0%) 883 (6·5%)
Dementia
No 55 758 (76·2%) 28 473 (78·3%) 9548 (80·3%) 13 583 (76·5%) 6708 (84·9%) 7079 (78·9%) 2237 (71·8%) 11 449 (84·9%)
Yes 11 682 (16·0%) 5668 (15·6%) 1624 (13·7%) 3064 (17·3%) 750 (9·5%) 1306 (14·6%) 645 (20·7%) 1239 (9·2%)
Data missing 5757 (7·9%) 2226 (6·1%) 723 (6·1%) 1105 (6·2%) 443 (5·6%) 588 (6·6%) 233 (7·5%) 798 (5·9%)
Smoking
Never smoked 23 944 (32·7%) 11 976 (32·9%) 4071 (34·2%) 5577 (31·4%) 2811 (35·6%) 2872 (32·0%) 889 (28·5%) 4894 (36·3%)
Current smoker 3895 (5·3%) 1927 (5·3%) 677 (5·7%) 875 (4·9%) 508 (6·4%) 459 (5·1%) 188 (6·0%) 694 (5·1%)
Former smoker 15 834 (21·6%) 8533 (23·5%) 2914 (24·5%) 4179 (23·5%) 1740 (22·0%) 2317 (25·8%) 630 (20·2%) 3304 (24·5%)
Data missing 29 524 (40·3%) 13 931 (38·3%) 4233 (35·6%) 7121 (40·1%) 2842 (36·0%) 3325 (37·1%) 1408 (45·2%) 4594 (34·1%)
Data are n or n (%). No means patients didn’t have the comorbidity or characteristic, yes means they did. IMD=Index of Multiple Deprivation. *Severe acute respiratory infection was contained within case 
definition so was not counted as a complication. †1=least deprived, 5=most deprived. ‡Includes West Asian, Latinx, Aboriginal, and First Nations People.
Table 1: Patient characteristics by organ-specific complications
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system were at higher risk of developing a complication 
affecting the same organ (appendix pp 45–46). The 
relationship between increasing age, male sex, and 
the risk of complications persisted independent of 
the number of comorbidities (figure 3A and appendix 
pp 39–44). The risk of complications and relationship 
between age and risk of complications were comparable 
across all comorbidity groups.
In patients who survived to 28 days from first symp -
toms to discharge, 44·9% (23 619 of 52 582) suffered 
complications, compared with 61·9% (12 624 of 20 384) 
in those who died within 28 days. Complications were 
more common in those requiring respiratory support 
and were highest in patients who received critical care 
(8267 [82·4%] of 10 034) or invasive mechanical ventila tion 
(5619 [91·7%] of 6122; table 2). The presence and number of 
complications was significantly associated with worse in-
hospital survival (figure 2B). Following adjustment for age, 
sex, deprivation, and hospital, the occurrence of any 
complication was significantly associated with poorer 
overall survival (figure 2C). Cardiovascular (hazard ratio 
1·98, 95% CI 1·85–2·11) and complex respiratory com-
plications (2·15, 2·04–2·27) were most strongly associated 
with worse outcomes. After adjusting for age, sex, and 
deprivation, patients having an acute kidney injury were 
4 times more likely to be admitted to critical care, and 
those with respiratory complications were 13 times more 
likely to be admitted to critical care (figure 2D).
When the relationships between complications and 
mor tality were modelled using generalised additive 
models and plotted (figure 3B and appendix pp 39–44), the 
presence of any complication, in addition to increasing age 
and male sex, was associated with death. In younger 
people, the presence of a complication was associated with 
a large increase in the risk of mortality, compared with 
older people, in which the presence of a complication was 
associated with a much smaller increase in mortality. 
Associations between complications and mortality were 
similar across comorbidity groups overall, but we identified 
that in younger people with comorbidities, mortality was 
much higher in those who had complications compared 
with people of the same age without complications. 
Respiratory and cardiovascular complications were 
associated with the largest increases in death across all 
ages, whereas those with neurological or systemic 
Figure 2: Outcomes and mortality after complications
(A) Differences in complication rates, age, sex, and comorbidity. (B) Kaplan-Meier 
survival curve stratified by number of complications had. The hazard ratios are: 
no complications 1 (reference level); one complication 1·50 (95% CI 1·45–1·55, 
p<0·0001); two complications 1·87 (1·80–1·94, p<0·0001); three complications 
2·39 (2·29–2·50, p<0·0001); four complications 2·64 (2·50–2·79, p<0·0001); 
and five complications 2·81 (2·67–2·95, p< 0·0001). (C) Hazard ratios for effect of 
organ-specific complications on overall survival, adjusted for age, sex, indices of 
multiple deprivation quintile, and study centre (appendix pp 14–20). (D) Effect of 
organ-specific complications on odds of being admitted to critical care (appendix 
pp 21–27). Error bars represent 95% CIs.
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complications were most likely to survive (appendix 
pp 39–44).
Physiology-based early warning scores and the 4C 
Mortality Score, calculated using parameters at hospital 
admission, were associated with the occurrence of 
complications in survivors. Higher 4C Mortality Score on 
admission corresponded with an increased probability 
of at least one complication (appendix p 47). Similarly, 
higher NEWS2 and qSOFA scores on admission were 
associated with an increased probability of one or more 
complications (appendix p 47). The number of symptoms 
on admission did not appear to be related to the incidence 
of complications (appendix p 47).
In those who survived, 26·6% (13 309 of 50 105) of 
patients had worse ability to self-care than they did before 
their illness (figure 4A). This worsening of ability 
increased with age, male sex, and in those who received 
critical care support (figures 4A, B). Having a complication 
was independently associated with an increased risk of 
worse ability to self-care after discharge after adjusting 
for age, sex, deprivation, and hospital (adjusted odds 
ratio 2·42, 95% CI 2·31–2·54; figure 4C). Neurological 
complications had the strongest associations with worse 
functional outcome (4·39, 3·95–4·63; figure 4C).
Discussion
Hospitalisation with COVID-19 is associated with high 
rates of morbidity in adults. Almost half of the survivors 
had one or more complications, which were more 
likely in patients who required critical care. Survivors of 
COVID-19 who had suffered at least one complication 
had a lower ability to self-care on discharge from hospital. 
The effect of complications on the ability to self-care was 
most profound in younger patients (aged <50 years). We 
found that complication rates were high in every age 
group and increased with age. Unlike mortality, there 
were only small differences in complication rates in 
groups stratified by pre-existing comorbidity. Males were 
significantly more likely to develop complications than 
females.
The most common complications in our data were 
acute kidney injury, and complex respiratory and sys-
temic complications. Although our study only looked at 
complications during the first admission for COVID-19, 
many of the common complications identified are 
associated with substantial long-term morbidity. Acute 
kidney injury is known to be associated with increased 
long-term hazards of mortality, requirement for dialysis, 
and an increase in cardiovascular events.19–21 In addition 
to the more common complications identified, rarer 
complications including stroke, congestive heart failure, 
and cardiac arrest were present in 1–5% of patients.22–24 
Patients who received critical care had the highest 
complication rates, compatible with previous observations 
describing high levels of morbidity in those who require 
critical care.6,8,25,26 The least commonly observed were 
neurological complications, although these were the most 
strongly associated with reduced ability to self-care. 
Suspected bacterial pneumonia and likely ARDS were 
the most common respiratory complications. When 
compared with the published literature on influenza, 
complications rates in patients with COVID-19 were the 
same or higher.27–29 Notably, this higher rate of com-
plications appears to be primarily driven by non-infectious 
complications, as the rates of secondary bacterial infection 
in patients with COVID-19 were lower than described in 
influenza.30 In particular, COVID-19 patients had up to 19 
times the risk of developing likely ARDS when compared 
with patients admitted with influenza.31
Most clinical studies of COVID-19 have focused on 
associated mortality.1 Mortality is a hard endpoint, easily 
measured, and of utmost importance. However, its use as 
Figure 3: Relationship between age, sex, comorbidities, and adjusted outcomes using generalised additive 
models
(A) Relationships for the outcome of adjusted risk of any complication. (B) Relationships for the outcome of 
adjusted mortality risk, stratified by presence of complications. Each line represents one bootstrap replicate 
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a sole outcome in COVID-19 studies might under-
estimate the detrimental impact of COVID-19, particularly 
in those who are younger or otherwise healthy. Our 
analysis suggests that the odds of some complications 
change little with increasing age in those older than 
50 years. Therefore, when compared with mortality, 
complications will affect many more people across a 
range of different age groups. Notably, our data show only 
small increases in the risk of complications by pre-
existing comorbidities. The effect of comorbidities on the 
risk of complications and death was substantially higher 
in younger people compared with people without comor-
bidities of the same age. We also observed the differences 
in number of complications decrease between those who 
died and those who survived as age increased, suggesting 
that although young people are less likely to die, they 
might be proportionally more likely to survive and live 
with complications. Patients with complications are 
also likely to have impaired ability to self-care following 
discharge from hospital. This finding contradicts current 
narratives that COVID-19 is only dangerous in people 
with existing comorbidities and the elderly. Dispelling 
and contributing to the scientific debate around such 
narratives has become increasingly important. Many 
countries including the UK are experiencing further 
waves of infection.32 Suggestions have been made around 
using younger, healthy demo graphic groups who are less 
likely to die, to help support economic output, and to 
propagate herd immunity within a population.33 Policy 
makers need to consider not just mortality when making 
decisions around easing population-level interventions 
designed to limit spread, but also the risk of both short-
term and long-term complications for those who survive 
COVID-19.
Our data provide the most comprehensive, multicentre, 
systematic analysis of the effect of COVID-19 on short-
term clinical outcomes in a hospitalised population, 
including patient groups from both ward level and 
critical care. Data were collected prospectively and 
capture most people hospitalised with COVID-19 in the 
UK. Recruitment to our study con tinues, enabling us to 
capture trends and incidence of complications in near 
real time. Other smaller, or single centre studies, have 
typically focused either exclusively on patients who 
received critical care, or on one type of complication and 
lack systematic approaches to data collection.4,34–38 Our 
study identifies high rates of com plications and the risk 
factors for developing these, and describes severity, 
which previous studies have been unable to do at scale. 
In particular, we find that in the short term, respiratory 
and cardiovascular complications have the strongest 
association with mortality. A further strength is that our 
study includes patients in both critical care and in 
ward-level areas, whereas other groups have just studied 
intensive care populations.39 In addition, the multicentre 
nature of our study across 302 facilities in four countries 
increases the generalisability of our findings, which is 
particularly important to provide robust estimates of 
Patients having complications Organ-specific complications
Total number of 
patients
Any complication Systemic Renal Gastrointestinal 
(including liver)
Cardiovascular Neurological Respiratory*
Total number of patients 73 197 36 367 (49·7%) 11 895 (16·3%) 17 752 (24·3%) 7901 (10·8%) 8973 (12·3%) 3115 (4·3%) 13 486 (18·4%)
Death
No 50 105 (68·5%) 21 784 (59·9%) 7423 (62·4%) 10 059 (56·7%) 4837 (61·2%) 4035 (45·0%) 1880 (60·4%) 7028 (52·1%)
Yes 23 092 (31·5%) 14 583 (40·1%) 4472 (37·6%) 7693 (43·3%) 3064 (38·8%) 4938 (55·0%) 1235 (39·6%) 6458 (47·9%)
Critical care admission
No 62 125 (84·9%) 28 092 (77·2%) 8804 (74·0%) 12 992 (73·2%) 5139 (65·0%) 6640 (74·0%) 2446 (78·5%) 7472 (55·4%)
Yes 10 034 (13·7%) 8267 (22·7%) 3090 (26·0%) 4755 (26·8%) 2760 (34·9%) 2333 (26·0%) 668 (21·4%) 6012 (44·6%)
Data missing 1038 (1·4%) 8 (<0·1%) 1 (<0·1%) 5 (<0·1%) 2 (<0·1%) 0 1 (<0·1%) 2 (<0·1%)
Any invasive ventilation
No 65 888 (90·0%) 30 710 (84·4%) 9556 (80·3%) 14 262 (80·3%) 5815 (73·6%) 7186 (80·1%) 2573 (82·6%) 8809 (65·3%)
Yes 6122 (8·4%) 5619 (15·5%) 2330 (19·6%) 3471 (19·6%) 2077 (26·3%) 1784 (19·9%) 542 (17·4%) 4670 (34·6%)
Data missing 1187 (1·6%) 38 (0·1%) 9 (0·1%) 19 (0·1%) 9 (0·1%) 3 (<0·1%) 0 7 (0·1%)
Any non-invasive ventilation
No 60 035 (84·7%) 28 202 (78·5%) 9228 (78·2%) 13 361 (76·1%) 5685 (72·8%) 6862 (77·1%) 2566 (83·3%) 8332 (62·3%)
Yes 10 827 (15·3%) 7741 (21·5%) 2567 (21·8%) 4194 (23·9%) 2124 (27·2%) 2034 (22·9%) 513 (16·7%) 5038 (37·7%)
Any oxygen
No 17 652 (24·7%) 5971 (16·5%) 2079 (17·6%) 2470 (14·0%) 1153 (14·7%) 1190 (13·3%) 737 (23·8%) 838 (6·2%)
Yes 53 695 (75·3%) 30 181 (83·5%) 9762 (82·4%) 15 189 (86·0%) 6705 (85·3%) 7744 (86·7%) 2358 (76·2%) 12 598 (93·8%)
Data are n or n (%). No means patients did not have the clinical outcome specified in the table rows, yes means they did. *Severe acute respiratory infection was contained within case definition so was not 
counted as a complication.
Table 2: Outcomes by organ-specific complications
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Figure 4: Relationship between in-hospital complications and ability to self-care at time of discharge or transfer to other health-care facility
(A) Ability to self-care at discharge in patients who had complications by age group and sex. (B) Ability to self-care at discharge by disease severity. (C) Adjusted odds 

















































































Proportion of patients worse than
before illness (%)
Ward-level care
0 25 50 75 100
0 25 50 75 100
Proportion of patients worse than
before illness (%)
0 25 50 75 100
Critical care admission
0 25 50 75 100
Mechanical ventilation
0 25 50
Proportion of patients worse
than before illness (%)
Proportion of patients worse
than before illness (%)
Proportion of patients worse


































































































234 www.thelancet.com   Vol 398   July 17, 2021
short-term morbidity for health-care planners and policy 
makers. The large sample size of our study allowed us to 
do meaningful subgroup analyses and integrate blood 
test and microbiology results to increase robustness. 
This size also meant we could detect rare events in 
important patient groups such as those receiving critical 
care, younger patients, and survivors where complications 
might have the biggest effect and be with patients for a 
long period of time after the initial event.
This study has important implications for clinicians. It 
was not possible for us to causally link complications and 
consequent poor outcomes. However, it is plausible 
that interventions targeted at preventing in-hospital 
com plications or reducing their impact could plausibly 
improve outcomes. We found respiratory and cardio-
vascular complications were associated with greatest 
severity and acute kidney injury was one of the most 
common. Treatments such as enhanced monitoring and 
early treatment for patients for cardiac arrhythmias that 
might lead to further problems such as stroke or cardiac 
arrest might, therefore, be useful. Similarly, for acute 
kidney injury, optimising fluid balance to ensure adequate 
renal perfusion in patients with less severe respiratory 
disease might lessen the impact of acute kidney injury. 
Our data also present research opportunities for 
preventing complications that contribute to substantial 
disability. For example, further characterisation of 
thromboembolic complications and stroke can help to 
identify optimal anti coagulation strategies in patients with 
COVID-19.40 We found initial disease severity, measured 
using the 4C Mortality Score, qSOFA, and NEWS, were 
associated with the presence of complications, and could 
therefore be useful tools to stratify those at the highest 
risk of developing complications in clinical practice and 
interventional trials.
There are several limitations to our study, which relate 
to the design and current unknowns in COVID-19 
research. First, this dataset focuses on in-hospital 
complications during the index admission for COVID-19 
and does not provide longer-term outcome data or data 
on quality of life. Nevertheless, our results suggest that 
complications of COVID-19 might affect all survivor 
groups, rather than just those who are older and have 
comorbidities. Second, the complications that were 
captured were predefined by a pragmatic outbreak 
preparedness study protocol, and case report forms 
developed for disease X, long before the emergence of 
SARS-CoV-2. The outcomes we chose are both clinically 
important and associated with complications observed in 
other infec tious viral diseases. Local investigators could 
enter other complications as free text, but this approach 
might have missed some important outcomes that were 
otherwise unexpected (ie, venous thromboembolism); 
however, as these emerged we amended the case report 
form to include these. This suggests that our estimates 
are likely to be conservative, when compared with the 
incidence of some complications (including pulmonary 
embolism or deep vein thrombosis) found in other 
smaller studies. Similarly, these studies are more likely 
to focus on populations with higher COVID-19 severity, 
where our study captured all hospital admis sions.41 This 
protocol did not include a non-SARS-CoV-2 comparator 
group, which could provide useful data to compare 
complication burdens to other causes of critical illness or 
viral infection. Third, owing to logistical constraints, we 
did not capture data on the timings of each complication. 
As our study was an urgent response to the emerging 
pandemic, it would not have been possible to identify 
exactly when each complication started for such a large 
number of patients. Data around timings could in the 
future help to identify sequences of events that lead to 
further deterioration. Fourth, our data can only provide 
estimates of who gets complications in a hospitalised 
population. We found that even in previously healthy 
adults with no recorded comorbidity, complications 
affected more than four in ten hospitalised patients; 
the effect and burden in the community remains 
undescribed. For infection-related outcomes, we sys-
tematically classified microbiological culture results to 
identify whether infections were caused by pathogenic 
organisms. However, individuals might have acquired 
these in the community, so our estimates encompass 
both hospital and community acquired infection. In 
addition to this, the UK health service was under 
considerable pressure, which could have resulted in 
preferential admission to hospital of patients with the 
most severe disease. This might lead to an increase in the 
observed complication rate, as individuals with milder 
disease were managed at home. However, the risk of this 
is reduced by the multicentre design of our study, as 
peaks in hospital admissions varied in the UK over time. 
Compared with other international cohorts, our study 
had a higher observed hospital case fatality rate.42–45 The 
reasons for this are multifactorial, and could relate to 
differences in testing strategy, thresholds for hospital 
admission, pre-existing population morbidity, and 
health-care system preparedness. Finally, our data were 
collected from real-world observed clinical practice and 
patients did not undergo any additional tests to detect the 
presence of complications. Therefore, the true burden of 
complications is likely to be higher. However, doing large 
numbers of invasive tests might not be acceptable for 
patients, particularly in patients who are unlikely to 
survive or cannot tolerate investigations, and would be 
logistically challenging in a study of this size.
Policy makers and health-care planners should 
anticipate that large amounts of health and social care 
resources will be required to support those who survive 
COVID-19. This includes adequate provision of staffing 
and equipment; for example, provision of follow-up clinics 
for those who have sustained in-hospital complications 
such as acute kidney injury or respiratory tract infection. 
Beyond the short term, further work is underway to 
establish the consequences of these complications and 
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whether these are transient or linked to worse long-term 
outcomes. Data on long-term health difficulties posed by 
COVID-19 will be of great importance, particularly as a 
large proportion of COVID-19 survivors come from 
economically active age groups. This should be considered 
on a policy level in terms of return to work and education; 
but importantly, it could have effects on individual 
behaviour around perceived benefits of engaging with 
preventive measures including vaccination.
In summary, high rates of complications and poor 
functional outcomes were present in survivors of 
COVID-19, including in young and previously healthy 
individuals. Those aged older than 50 years and admitted 
to critical care were at the highest risk. Common 
COVID-19 complications identified in this Article are 
known to be associated with long-term morbidity and an 
increased risk of death.
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